关于预计 2026 年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 1、2026 年 1 月 15 日，公司第五届董事会第二十二次会议审议通过了《关 于预计 2026 年度日常关联交易的议案》，关联董事张许科先生、秦德超先生、 胡伟先生、宋永军先生、裴莲凤女士、赵锐先生回避表决。 2、公司 2026 年度预计日常关联交易金额 3,924.00 万元，占公司 2024 年度 经审计净资产的 1.49%，在董事会决策权限范围内，无需提交股东会审议。 证券代码：603566 证券简称：普莱柯 公告编号：2026-003 普莱柯生物工程股份有限公司 3、本议案在审议前已经公司独立董事专门会议审议通过。公司独立董事对 本事项发表了书面意见，认为：公司 2026 年度预计日常关联交易符合《中华人 民共和国公司法》《公司章程》等相关规定，公司与关联方之间发生的交易基于 公司经营需要，交易定价公允、合理，日常关联交易额度的预计符合交易双方业 务 ...

Market Overview - The animal health sector experienced a decline of 0.44% on January 14, with Haili Biological leading the drop [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] Stock Performance - Notable gainers included: - Qudongli (code: 920275) with a closing price of 10.39, up 10.65% on a trading volume of 112,300 shares and a turnover of 118 million yuan [1] - Huisheng Biological (code: 300871) closed at 25.52, up 1.84% with a trading volume of 270,100 shares and a turnover of 696 million yuan [1] - Major decliners included: - Haili Biological (code: 603718) closed at 6.55, down 1.65% with a trading volume of 237,400 shares and a turnover of 157 million yuan [2] - Zhongmu Co., Ltd. (code: 600195) closed at 7.92, down 1.61% with a trading volume of 201,400 shares and a turnover of 161 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 140 million yuan from institutional investors, while retail investors experienced a net inflow of 52.14 million yuan [2] - The detailed capital flow for selected stocks showed: - Huisheng Biological had a net inflow of 23.06 million yuan from institutional investors [3] - ST Green Kang (code: 002868) faced a significant net outflow of 5.87 million yuan from institutional investors [3]

Core Insights - The strategic partnership between Zhejiang Haizheng Animal Health Products Co., Ltd. and Zhongyu Pet Food Co., Ltd. aims to launch a pet prescription food project, establishing a joint venture named Zhejiang Haizheng Zhongyu Animal Nutrition Technology Co., Ltd. focusing on production, research, and sales of pet prescription food [2][8] Investment and Financials - The total investment for the joint venture is projected to be 236 million yuan, with an approved investment amount of 204 million yuan [5] - Haizheng Animal Health has previously announced a 200 million yuan investment to establish a wholly-owned subsidiary for the pet prescription food project, which includes the construction of two intelligent production lines [5][12] Market Position and Strategy - The pet prescription food market is a niche segment centered around "nutritional formulas," with significant growth potential as the domestic market is estimated to be worth 1 to 1.5 billion yuan [7][13] - The partnership is expected to leverage Zhongyu Pet Food's strong production capabilities and supply chain, as it serves over 300 brands globally [9][10] Development Plans - The focus for the next 1-2 years will be on developing formulas, researching processes, and conducting clinical trials to validate the effectiveness of the pet prescription food [11][12] - The project will be implemented in two phases, with the first phase expected to take 24 months, aiming for an annual production capacity of 10,000 tons upon completion [12] Competitive Landscape - The domestic prescription food market is currently dominated by international brands like Royal Canin and Hill's, but there is a growing demand for reliable domestic options as the pet population ages [13] - The company aims to provide a comprehensive health solution for pets, covering pharmaceuticals, health products, and prescription food [13]

Investment Rating - The industry is rated as "Leading the Market - A" with a maintained rating [5]. Core Views - The recent pig prices are expected to fluctuate within a range, with a focus on changes in production capacity [19][21]. - The white feather chicken market is experiencing a supply-demand mismatch, with stable prices but cautious market sentiment [33]. - The aquaculture sector shows stable prices, presenting potential investment opportunities [47]. Summary by Sections 1. Weekly Market Review - The agricultural sector increased by 0.98% during the latest trading week, ranking 29th among the primary industries [12]. - The animal health sector saw significant gains, with notable increases in specific stocks [15]. 2. Industry Data Tracking 2.1. Pig Farming - The average price of live pigs is 12.49 CNY/kg, with a week-on-week increase of 1.54% and a two-week increase of 4.22% [18]. - The average price of piglets is 363 CNY/head, stable over the past two weeks [19]. - The average daily slaughter volume of pigs is 226,500 heads, showing a week-on-week decrease of 5.12% [19]. 2.2. Poultry Farming - The average price of white feather chicken is 7.64 CNY/kg, down 1.04% week-on-week [33]. - The price of chicken seedlings is 3.59 CNY/bird, up 1.70% week-on-week [33]. - The market is stable, but there is a notable increase in inventory levels due to weak demand [33]. 2.3. Planting Sector - The average price of corn is 2,352.77 CNY/ton, with a slight increase of 0.02% week-on-week [42]. - The average price of domestic wheat is 2,512.98 CNY/ton, down 0.12% week-on-week [42]. - The average price of domestic soybeans is 4,048.42 CNY/ton, up 0.50% week-on-week [42]. 2.4. Aquaculture Sector - The average price of carp is 20.00 CNY/kg, stable week-on-week, with a year-on-year increase of 11.11% [47]. - The average price of crab is 260.00 CNY/kg, showing a significant year-on-year increase of 30.00% [47]. - The average price of shrimp is 320.00 CNY/kg, stable week-on-week but down 11.11% year-on-year [47].

Group 1 - Shoukai Co. achieved a signed area of 125.72 million square meters and a signed amount of 17.845 billion yuan in 2025 [1] - Tongda Hai expects a net loss for the year 2025 [2] - Jiuri New Materials' subsidiary has entered the trial production phase for a project with an annual capacity of 350 tons of hydroxy ketone [3] Group 2 - Jixin Technology's shareholder plans to reduce their stake by up to 1% [4] - Fulai New Materials received approval from the CSRC for a stock issuance [5] - Yaqi International plans to sign a strategic cooperation framework agreement with Zhongnong Holdings [6] Group 3 - Sanwei Co.'s controlling shareholder plans to transfer up to 5.10% of shares [7] - Lekai Film's subsidiary plans to invest 97.6675 million yuan in a TAC functional film production line [8] - China Power Construction's subsidiary signed two major contracts totaling approximately 15.589 billion yuan [9] Group 4 - Shunhao Co. plans to increase its investment in a subsidiary by 74.98 million yuan [10] - Jieneng Wind Power reported a cumulative power generation of 12.417 billion kWh in 2025, a year-on-year increase of 1.43% [11] - Zhongjian Technology's H-share issuance application has been accepted by the CSRC [12] Group 5 - Hendi Pharmaceutical expects a net profit decrease of 57.4% to 66.14% in 2025 [13] - Haopeng Technology anticipates a net profit increase of 113.69% to 141.09% in 2025 [14] - Lingang Co. expects a net loss of 1.45 billion to 1.67 billion yuan in 2025 [15] Group 6 - Chuan Investment Energy reported a cumulative power generation of 6.627 billion kWh in 2025, a year-on-year increase of 13.85% [16] - Tengyuan Cobalt expects a net profit increase of 50.02% to 69.87% in 2025 [17] - Huazhi Jie plans to repurchase shares worth 30 million to 50 million yuan [18] Group 7 - Opto has won a bid for a 120 million yuan project from GoerTek [19] - Shanghai Construction reported a new contract amount of 252.942 billion yuan in 2025, a year-on-year decrease of 34.98% [20] - Hangfa Control expects a net profit decrease of 52.02% to 58.02% in 2025 [22] Group 8 - Shimao Energy is planning a change in control and will continue to suspend trading [23] - Shenwan Hongyuan Securities received approval for a bond issuance of up to 60 billion yuan [24] - Jingjiawei signed a strategic cooperation letter of intent with Jing'an Technology [25] Group 9 - Pianzaihuang completed the first subject enrollment for a clinical trial of a new drug [26] - Placo's subsidiary received a new veterinary drug registration certificate [27] - Zhongli Co. plans to reduce its stake by up to 0.75% [28] Group 10 - Solar Energy received renewable energy subsidies of 3.318 billion yuan in 2025, a year-on-year increase of 142.9% [29] - Palm Co. has filed a lawsuit to recover 144 million yuan in project payments [30][31] - Yongjin Co. plans to invest 2.658 billion yuan in a new stainless steel project [32] Group 11 - BAIC Blue Valley plans to increase its stake by 14.5 million to 16.4 million yuan [33] - Lingyun Light's stock issuance application has been approved by the CSRC [34] - Hongbo New Materials expects a net loss in 2025 [35] Group 12 - Shanghai Pharmaceuticals received approval for the listing of a new antifungal drug [36] - Changjiang Electric reported a net profit of 34.167 billion yuan in 2025, a year-on-year increase of 5.14% [37] - Weilan Bio received a new veterinary drug registration certificate [38] Group 13 - Pingzhi Information's subsidiary is expected to win a procurement project worth approximately 37.5884 million yuan [39]

Core Viewpoint - The approval of a new veterinary drug, a trivalent inactivated vaccine for Newcastle disease, avian influenza (H9 subtype), and infectious bursal disease, represents a significant advancement for the poultry industry, addressing critical diseases that cause substantial economic losses [1] Company Summary - The company,普莱柯 (603566.SH), announced the approval of its wholly-owned subsidiary, 洛阳惠中生物技术有限公司, for a new veterinary drug [1] - The new vaccine is officially registered as of January 12, 2026, under the Ministry of Agriculture and Rural Affairs of the People's Republic of China [1] Industry Summary - Newcastle disease, avian influenza (H9 subtype), and infectious bursal disease are major infectious diseases that severely impact the poultry industry, leading to significant economic losses [1] - The new trivalent inactivated vaccine offers several advantages: 1. Utilizes suspension cell culture technology for more controllable and efficient production [1] 2. Achieves high soluble expression of VP2 protein for infectious bursal disease in a baculovirus vector [1] 3. Provides immunity lasting over 4 months and allows for multi-disease prevention with a single injection, reducing stress on chicken populations from frequent vaccinations [1]

关于子公司获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经农业农村部审查，批准 普莱柯生物工程股份有限公司（以下简称"公司"）全资子公司洛阳惠中生物技 术有限公司等单位联合申报的"鸡新城疫、禽流感（H9 亚型）、传染性法氏囊 病三联灭活疫苗（La Sota 株+SW001 株+VP2 蛋白，悬浮培养）"为新兽药，并 于 2026 年 1 月 12 日公示了核发《新兽药注册证书》（中华人民共和国农业农村 部公告第 987 号）事项。详情如下： 一、新兽药的基本信息 新兽药名称：鸡新城疫、禽流感（H9 亚型）、传染性法氏囊病三联灭活疫 苗（La Sota 株+SW001 株+VP2 蛋白，悬浮培养） 证券代码：603566 证券简称：普莱柯 公告编号：2026-002 普莱柯生物工程股份有限公司 鸡新城疫、禽流感（H9 亚型）、传染性法氏囊病均是严重危害养禽业的重 要传染病之一，给养鸡业造成巨大的经济损失。鸡新城疫、禽流感（H9 亚型）、 传染性法氏囊病三联灭 ...

Core Insights - The animal health sector experienced a rise of 1.09% on January 13, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Stock Performance - Huisheng Biological (300871) closed at 25.06, up 8.39%, with a trading volume of 276,700 shares and a transaction value of 700 million [1] - Other notable performers included: - Qudongli (920275) at 65.6, up 3.99% [1] - Haili Biological (603718) at 6.66, up 1.99% [1] - Xianfeng Holdings (002141) at 3.77, up 1.34% [1] - Shunlian Biological (688098) at 9.78, up 1.03% [1] Capital Flow - The animal health sector saw a net inflow of 34.99 million from institutional investors, while retail investors contributed a net inflow of 30.94 million [2] - However, speculative funds experienced a net outflow of 65.94 million [2] Individual Stock Capital Flow - Major net inflows were observed in: - Biological Shares (600201) with a net inflow of 39.54 million [3] - Jinhe Biological (002688) with a net inflow of 13.45 million [3] - Xianfeng Holdings (002141) with a net inflow of 10.20 million [3] - Conversely, significant net outflows were noted in: - Biological Shares (600201) with a net outflow of 48.25 million from speculative funds [3] - Jinhe Biological (002688) with a net outflow of 1.46 million from retail investors [3]

Core Viewpoint - The company has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug, which will enhance its product offerings in the poultry vaccine market [1] Group 1: Product Development - The new veterinary drug is a trivalent inactivated vaccine for preventing Newcastle disease, H9 subtype avian influenza, and infectious bursal disease [1] - The vaccine is characterized by efficient production, high expression, and long-lasting immunity [1] Group 2: Market Impact - The approval of the new veterinary drug certificate will enrich the company's poultry vaccine product line and improve its competitive edge in the market [1]

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Luoyang Huizhong Biotechnology Co., Ltd., has received a new veterinary drug registration certificate for a trivalent inactivated vaccine targeting three chicken diseases, enhancing the company's product portfolio and competitiveness in the poultry vaccine market [1] Group 1 - The vaccine is designed to prevent three diseases: Newcastle disease, avian influenza (H9 subtype), and infectious bursal disease [1] - The registration certificate was issued by the Ministry of Agriculture and Rural Affairs on January 12, 2026, marking a significant regulatory milestone for the product [1] - The vaccine is classified as a Category III new veterinary drug, indicating its potential impact on animal health and the poultry industry [1] Group 2 - The product still requires approval for veterinary drug product registration before it can be marketed, indicating further steps in the regulatory process [1] - This development enriches the company's poultry vaccine offerings, which is expected to enhance its competitive edge in the market [1]